tiprankstipranks
Advertisement
Advertisement

BLTE Stock Latest News

Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
Company AnnouncementsBelite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
12d ago
BLTE
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
PremiumCompany Announcements
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
13d ago
6K
BLTE
Belite Bio Eyes 2027 Launch After Pivotal Win
PremiumCompany Announcements
Belite Bio Eyes 2027 Launch After Pivotal Win
1M ago
BLTE
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
PremiumThe Fly
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
1M ago
BLTE
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
PremiumThe Fly
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
1M ago
BLTE
Belite Bio price target raised to $217 from $187 at Benchmark
PremiumThe FlyBelite Bio price target raised to $217 from $187 at Benchmark
1M ago
BLTE
Belite Bio price target raised to $201 from $191 at Morgan Stanley
Premium
The Fly
Belite Bio price target raised to $201 from $191 at Morgan Stanley
1M ago
BLTE
Belite Bio price target raised to $200 from $195 at BofA
Premium
The Fly
Belite Bio price target raised to $200 from $195 at BofA
1M ago
BLTE
Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
PremiumRatings
Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
1M ago
BLTE
Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
PremiumThe Fly
Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
1M ago
GD
VG
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win
PremiumCompany Announcements
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win
1M ago
6K
BLTE
Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)
PremiumThe Fly
Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)
1M ago
BLTE
Belite Bio sees FY25 adjusted EPS ($1.15) vs. ($89c) last year
PremiumThe FlyBelite Bio sees FY25 adjusted EPS ($1.15) vs. ($89c) last year
1M ago
BLTE
Is BLTE a Buy, Before Earnings?
Premium
Pre-Earnings
Is BLTE a Buy, Before Earnings?
1M ago
BLTE
Belite Bio price target raised to $223 from $194 at Mizuho
Premium
The Fly
Belite Bio price target raised to $223 from $194 at Mizuho
2M ago
BLTE
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease
PremiumCompany Announcements
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease
3M ago
6K
BLTE
Belite Bio completes enrollment in DRAGON II trial of tinlarebant
PremiumThe Fly
Belite Bio completes enrollment in DRAGON II trial of tinlarebant
3M ago
BLTE
Netflix, Meta upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Netflix, Meta upgraded: Wall Street’s top analyst calls
3M ago
AAP
AIR
Belite Bio initiated with a Buy at BofA
PremiumThe Fly
Belite Bio initiated with a Buy at BofA
3M ago
BLTE
Belite Bio initiated with an Overweight at Morgan Stanley
PremiumThe FlyBelite Bio initiated with an Overweight at Morgan Stanley
3M ago
BLTE
Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential
Premium
Ratings
Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential
3M ago
BLTE
Belite Bio participates in a conference call with H.C. Wainwright
Premium
The Fly
Belite Bio participates in a conference call with H.C. Wainwright
4M ago
BLTE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >